Sebastian Rehberg,Michael Joannidis,Tony Whitehouse et al.
Sebastian Rehberg et al.
Landiolol is an injectable ultrashort acting beta-blocker with high beta1 selectivity indicated for heart rate control of atrial fibrillation in the emergency and critical care setting. Accordingly, landiolol is associated with a significan...
Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting [0.03%]
landiolol：药理学及其在急诊房颤心室率控制中的应用
Hans Domanovits,Michael Wolzt,Günter Stix
Hans Domanovits
This article provides new insight on landiolol, an ultra-short acting injectable betablocker, recently approved in Europe, with regard to its pharmacokinetic and pharmacodynamic profile, along with its first experience in Caucasian healthy ...
Martin Balik,Michael Sander,Helmut Trimmel et al.
Martin Balik et al.
Beta-blockers are a potential option to manage peri-operative atrial fibrillation. Landiolol is a new ultra-short beta-blocker with a half-life of only 4 minutes and very high beta-1 selectivity which has been used for treatment and prevent...
Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction [0.03%]
用于心脏功能不全患者的房颤心率控制管理的 Landiolol 研究
Stephan von Haehling,Jan Bělohlávek,Fikret Er et al.
Stephan von Haehling et al.
Atrial fibrillation (AFib) is frequently associated with heart failure. Guidelines for AFib management have been recently updated and include an algorithm for acute heart rate control based on left ventricular ejection fraction and haemodyn...
Betrixaban for prevention of venous thromboembolism in acute medically ill patients [0.03%]
用于急性内科疾病患者静脉血栓栓塞预防的贝曲匹帕相克斯钠注射液
Jan Beyer-Westendorf,Peter Verhamme,Rupert Bauersachs
Jan Beyer-Westendorf
Venous thromboembolism (VTE) is a common, potentially preventable cause of morbidity and mortality among acute medically ill patients. More than half of VTE events in this population occur after hospital discharge. Thus, providing extended-...
Menno V Huisman,Frederikus A Klok
Menno V Huisman
Venous thromboembolism (VTE) in acute medically ill patients is a leading cause of in-hospital morbidity and mortality. A majority of these VTE events occur post-discharge, and patients remain at increased VTE risk for up to 3 months post-d...
Reducing the burden of venous thromboembolism in the acute medically ill population with extended-duration thromboprophylaxis [0.03%]
延长疗程的血栓预防在急性内科疾病患者中的应用以减少静脉血栓栓塞的发病率
Walter Ageno,Beverley J Hunt
Walter Ageno
Hospitalized acute medically ill patients are vulnerable to venous thromboembolism (VTE), known as hospital-acquired thrombosis (HAT). The elevated risk of HAT is usually due to a combination of factors, with immobility and a prothrombotic ...
Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients [0.03%]
延长用药的贝曲匹帕ixa用于急性内科患者的血栓预防：新的标准疗法？
Alexander T Cohen
Alexander T Cohen
Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease [0.03%]
ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA共识文件：冠心病患者长期抗血小板治疗
Michele Massimo Gulizia,Furio Colivicchi,Maurizio Giuseppe Abrignani et al.
Michele Massimo Gulizia et al.
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the cornerstone of pharmacologic management of patients with acute coronary syndrome (ACS) and/or those receiving coronary stents. Long-term (>1 year) DAPT may ...